skip to Main Content

Picking the Winners: Study Sheds Light on Possible Best Targets for Pancreatic Cancer Vaccine

Newsfeed image, light gray text on dark gray background
Pancreatic cancer is known for its grim prognosis. But remarkably, a very small group of patients manage to beat the odds and survive. In the past few years, researchers at Memorial Sloan Kettering Cancer Center (MSK), led by physician-scientist Vinod Balachandran, have made groundbreaking discoveries about why a lucky few seem to avoid having their cancer return after surgery.

The key appears to be proteins in the pancreatic tumors, called neoantigens, which alert the immune system to keep the cancer at bay. This finding led to a promising clinical trial to treat people with pancreatic cancer by stimulating their immune system with neoantigen-based vaccines. Read more . . . 


Back To Top